The current status of secondary cytoreduction in ovarian cancer: a systematic review.
CONCLUSIONS: Secondary cytoreduction remains a viable treatment option for select patients for now, but this is entirely dependent on the highly anticipated overall survival results of DESKTOP III and SOC 1.
PMID: 32649655 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Hematology | Ovarian Cancer | Ovaries | Statistics | Study